SAKK 36/13 (#730)
Laufzeit: 01.01.2018 - 31.12.2040
imported
Kurzfassung
Combination of Ibrutinib and Bortezomib followed by Ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter phase I/II trial
